DTP-HepB vaccine
Appearance
Combination of | |
---|---|
DTP vaccine | Vaccine |
Hepatitis B vaccine | Vaccine |
Clinical data | |
Trade names | Tritanrix-HepB |
AHFS/Drugs.com | UK Drug Information |
Routes of administration | Intramuscular injection |
ATC code | |
Identifiers | |
CAS Number |
DTP-HepB vaccine is a combination vaccine whose generic name is diphtheria and tetanus toxoids and whole-cell pertussis and hepatitis B (recombinant) vaccine (adsorbed) or DTP-Hep B. It protects against the infectious diseases diphtheria, tetanus, pertussis, and hepatitis B.[1]
A branded formulation, Tritanrix-HepB manufactured by GlaxoSmithKline, was granted marketing approval in the EU in 1996. Marketing approval lapsed in 2014.[2]
A review conducted in 2012 concluded that there was insufficient evidence to determine differences in safety and efficacy between DTP-HepB vaccine and Hib vaccine administered separately and pentavalent DTP-HepB-Hib vaccine.[3]
References
[edit]- ^ World Health Organization; World Health Organization Department of Immunization, Vaccines and Biologicals (2004). Immunization in Practice: A Practical Guide for Health Staff. World Health Organization. p. 18. ISBN 9789241546515. Retrieved 15 July 2018.
- ^ "Tritanrix HepB". European Medicines Agency. Archived from the original on 15 July 2018. Retrieved 14 July 2018.
- ^ Bar-On ES, Goldberg E, Hellmann S, Leibovici L (April 2012). "Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB)". The Cochrane Database of Systematic Reviews. 4 (4): CD005530. doi:10.1002/14651858.CD005530.pub3. PMID 22513932.